Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hedera helix leaf extract, derived from the common ivy plant, is a herbal medicinal product widely utilized as an expectorant and mucolytic agent for respiratory conditions. Its therapeutic efficacy is primarily attributed to triterpene saponins, most notably alpha-hederin. Alpha-hederin exerts its effect by inhibiting the internalization of beta-2 adrenergic receptors (ADRB2) in bronchial smooth muscle and alveolar cells. By maintaining a higher density of these receptors on the cell surface, the extract enhances the responsiveness to endogenous adrenaline, resulting in bronchodilation, increased surfactant production, and reduced mucus viscosity. Zhejiang Conba Pharmaceutical Co., Ltd. is a significant developer and manufacturer of this extract, particularly in the form of oral solutions indicated for the treatment of acute tracheobronchitis and chronic inflammatory bronchial diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hedera helix leaf.